Can surgery used to treat fluid accumulation also help with Alzheimer’s? A Singapore trial is exploring this possibility

Date:

arly results from a small clinical trial at Changi General Hospital suggest the technique could lead to improvements in memory, mood and cognition.

Can surgery used to treat fluid accumulation also help with Alzheimer’s? A Singapore trial is exploring this possibility
Clinical Assistant Professor Jeremy Sun (left) and Clinical Assistant Professor Vincent Tay. (Photo: CNA/Khoo Bee Khim)

A surgical procedure – commonly used to treat lymphoedema, or painful fluid accumulation in the limbs – is being explored as the next form of treatment for Alzheimer’s disease right here in Singapore, announced Changi General Hospital (CGH) on Tuesday (Apr 7). 

The two-year trial, known as Cervical Lymphatico-Venous Bypass for Alzheimer’s Disease (CLyVeB-AD-1), is being conducted on four patients at CGH.

The procedure taps on the body’s lymphatic system, a waste-clearance pathway that uses the brain’s fluid to “wash” away metabolic waste such as Alzheimer’s disease-causing proteins, particularly during deep sleep.

“The lymphatic system basically helps to collect and drain fluid high in protein from the body back into the blood circulatory system,” explained Clinical Assistant Professor Vincent Tay, a consultant with CGH’s Plastic, Reconstructive & Aesthetic Surgery Service, Department of Surgery. He is also the principal investigator of the CLyVeB-AD-1 trial.

Using a microsurgical technique known as lymphaticovenous anastomosis (LVA), lymphatic structures such as lymph nodes on each side of the neck are connected to adjacent veins to improve clearance for the protein-carrying brain fluid. 

“The surgical principles are similar – creating bypass pathways for fluid drainage. By connecting neck lymphatic structures to veins to enhance the brain’s natural waste clearance system, we can potentially help clear the toxic proteins that accumulate in Alzheimer’s disease,” said Clinical Assistant Professor Jeremy Sun, the head and a senior consultant with CGH’s Plastic, Reconstructive & Aesthetic Surgery Service, Department of Surgery. 

The multidisciplinary team participating in the CLyVeB-AD-1 trial travelled to Hangzhou, China, where LVA was first used in the treatment of Alzheimer’s disease, to learn about the technique in 2024. 

The team then obtained approval from the Institutional Review Board, and is prospectively registered on clinicaltrials.gov. The CLyVeB-AD-1 trial is the first regulated clinical trial of its kind in Singapore and Southeast Asia. 

Clinical Assistant Professor Vincent Tay (left) and Clinical Assistant Professor Jeremy Sun (third from left) operating on an Alzheimer’s disease patient. (Photo: Changi General Hospital)

To date, four undisclosed patients with mild to moderate Alzheimer’s disease, and ranging from ages 61 to 73, have undergone the procedure. They have been monitored since undergoing the procedure in January 2025. 

Post-surgery, improvements in key issues such as memory loss, cognitive dysfunction and behavioural disturbances have been reported, the doctors said. 

Brain scans have also shown steady improvements at the six-month point, which could signal stability, they added. 

“One patient who had long-standing depression and anxiety seemed to be less anxious and had improved mood after the surgery,” said Adjunct Associate Professor Lim Si Ching, a senior consultant with CGH’s Department of Geriatric Medicine. 

“Another patient who had challenges with language became more interactive and communicated better after the surgery.”

An estimated 100,000 individuals live with dementia in Singapore and about 70 per cent of them have Alzheimer’s disease, the most common type of dementia.

Older medications do not change the progression of the disease but they help to lessen the symptoms. (Photo: CNA/Khoo Bee Khim)

“Current medical treatments can only slow disease progression to a certain extent, which is why CGH wanted to explore innovative treatment approaches,” said Clin Asst Prof Tay. 

For instance, the latest approved medication for Alzheimer’s disease, monoclonal antibodies, have been proven to slow down the disease’s progression in global landmark trials by targeting the proteins, said Clin Asst Prof Tay. However, there are side effects and patients have to be monitored every six months with brain scans, he said. 

Older medications do not change the progression of the disease, added Clin Asst Prof Sun, but they help to lessen the symptoms. 

“But the moment you stop the medication, the patient reverts to where he is at the stage of the disease.”

Source: CNA

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related

赚钱、存钱、逛超市!新加坡儿童博物馆新展,让孩子边玩边学理财

新加坡儿童博物馆全新互动展 “Money Town”正式开放, 通过沉浸式游戏体验, 帮助5至9岁儿童从小建立健康的金钱观念。

风靡全球VR大展登陆新加坡!一起探秘4500年前吉萨大金字塔

不用远赴埃及,在新加坡即可开启一场穿越时空的古埃及探险。现象级沉浸式VR项目《消失的法老》正式落地狮城,带领观众走进世界七大奇迹之一——吉萨大金字塔的内部秘境。

PSLE results to be released on Nov 24

Secondary 1 school choices and options can be submitted through the online portal from 11.30am on Nov 24 to 4.30pm on Nov 30.

狮城开唱|曹杨Young首场新加坡演唱会「仅你可见」正式官宣

曹杨Young,携全新「仅你可见For Your Eyes Only」演唱会首度来到新加坡举行个人演唱会。